BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ou HY, Wu YN, Yu CY, Chen CL, Hsu HW, Weng CC, Leung-Chit Tsang L, Huang TL, Tong YS, Lim WX, Cheng YF. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up. J Vasc Interv Radiol 2020;31:1784-91. [PMID: 33023805 DOI: 10.1016/j.jvir.2020.06.009] [Reference Citation Analysis]
2 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Minami Y, Kudo M. Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI. Liver Cancer 2015;4:106-14. [PMID: 26697413 DOI: 10.1159/000367733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
4 Bzeizi KI, Arabi M, Jamshidi N, Albenmousa A, Sanai FM, Al-Hamoudi W, Alghamdi S, Broering D, Alqahtani SA. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:6172. [PMID: 34944792 DOI: 10.3390/cancers13246172] [Reference Citation Analysis]
5 Nakaji S, Hirata N. Evaluation of the viability of hepatocellular carcinoma in the caudate lobe using contrast-enhanced endoscopic ultrasonography after transarterial chemoembolization. Endosc Ultrasound. 2016;5:390-392. [PMID: 28000631 DOI: 10.4103/2303-9027.190924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Veloso Gomes F, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, Pereira P, Ferreira AI, Luz JH, Spaepen E, Bilhim T, Coimbra É. Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. Journal of Vascular and Interventional Radiology 2018;29:841-9. [DOI: 10.1016/j.jvir.2018.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fiorentini G, Sarti D, Carandina R, Mulazzani L, Mincarelli C, Candelari R, Argirò R, Fiorentini C, Aliberti C. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncology 2019;15:695-703. [DOI: 10.2217/fon-2018-0425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016;50:418-26. [PMID: 27904450 DOI: 10.1515/raon-2015-0045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, Boucher LM, Hassanain M. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21:e480-e492. [PMID: 24940108 DOI: 10.3747/co.21.1829] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
10 Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi J. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Academic Radiology 2018;25:1363-73. [DOI: 10.1016/j.acra.2018.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
11 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015;10:e0133488. [PMID: 26230853 DOI: 10.1371/journal.pone.0133488] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
12 Wu ZJ, Xie YF, Chang X, Zhang L, Wu HY, Liu JB, Zhang JX, Sun P. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization. Med Sci Monit 2021;27:e929884. [PMID: 33967266 DOI: 10.12659/MSM.929884] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]